Author:incardatheraadmin

InCarda Presents Phase 2 Safety and Efficacy Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Heart Rhythm Society Conference in San Francisco

[caption id="attachment_23373" align="aligncenter" width="800"] Dr. Chris Dufton, SVP of Clinical Development, answering questions about INSTANT P2 at HRS 2022 in San Francisco.[/caption] Phase 2 INSTANT study results demonstrate rapid and reproducible restoration of normal heart rhythm with symptom resolution and a predictable and favorable safety profile...

InCarda Therapeutics Announces Publication of Phase 2 Data Demonstrating Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm Is Safe and Effective

The original article titled “Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm” published in the peer-reviewed journal, Circulation: Arrhythmia and Electrophysiology San Francisco, California, March 15, 2022 – InCarda Therapeutics, Inc. (InCarda) announces that...

Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm

Harry J.G.M. Crijns, Arif Elvan, Nadea Al-Windy, Ype S. Tuininga, Erik Badings, Ismail Aksoy, Isabelle C. Van Gelder, Prashanti Madhavapeddi, A. John Camm, Peter R. Kowey, Jeremy N. Ruskin, Luiz Belardinelli and the INSTANT Investigators* Originally published 24 Feb 2022 https://doi.org/10.1161/CIRCEP.121.010204Circulation: Arrhythmia and Electrophysiology. 2022;15   Click here...

InCarda Presents Phase 2 Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Atrial Fibrillation Symposium in New York

Phase 2 INSTANT study results demonstrate rapid restoration of normal heart rhythm with a predictable and favorable safety profile for orally inhaled flecainide.   [caption id="attachment_23370" align="aligncenter" width="800"] Meisa Propst, VP of Clinical Operations at InCarda, presented the P2 INSTANT Safety Analysis Poster at the 2022 AF...